Sign In
Buy PSTX
$9.50
+0 (+0%)
At Close: Apr 04, 2025
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
07:23am, Tuesday, 26'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in
Roche to acquire US-based Poseida Therapeutics
01:29am, Tuesday, 26'th Nov 2024
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
01:10am, Tuesday, 26'th Nov 2024
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
09:00am, Thursday, 14'th Nov 2024
Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclini
Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know
01:05pm, Tuesday, 12'th Nov 2024
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
04:05pm, Monday, 11'th Nov 2024
SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatment
Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates
06:56pm, Thursday, 07'th Nov 2024
Poseida Therapeutics, Inc. (PSTX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to loss of $0.35 per share a yea
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
04:05pm, Thursday, 07'th Nov 2024
Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target Cash flow positive for the first nine months of 2024; $
New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC Additional profiling of patient
Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Scientific Meeting SAN DIEGO , Oct. 24, 2024 /PRNewsw
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
08:00am, Thursday, 17'th Oct 2024
Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into earl
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
04:30pm, Thursday, 03'rd Oct 2024
Inclusion on list recognizes Poseida for employee sentiment and satisfaction SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell thera
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
11:47am, Monday, 30'th Sep 2024
Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to r
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPR
FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society
